

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 10

PATENT NO. : 7,012,133
APPLICATION NO.: 08/963,656
ISSUE DATE : March 14, 2006
INVENTOR(S) : Craig J. Gerard et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

<110> GERARD, CRAIG J.
GERARD, NORMA P.
MACKAY, CHARLES R.
PONATH, PAUL D.
POST, THEODORE W.
QIN, SHIXIN

<120> ANTIBODIES TO C-C CHEMOKINE RECEPTOR 3 PROTEIN

<130> 079259-0040

<140> 08/963,656
<141> 1997-11-03

<150> 08/720,565
<151> 1996-09-30

<150> PCT/US96/00608
<151> 1996-01-19

<150> 08/375,199
<151> 1995-01-19

<160> 18

<170> PatentIn version 3.5

MAILING ADDRESS OF SENDER (Please do not use customer number below):

McDermott Will & Emery
28 State Street
Boston, MA 02109

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

<210> 1
 <211> 1689
 <212> DNA
 <213> Homo sapiens
 <220>
 <221> modified_base
 <222> (1291)..(1291)
 <223> a, c, t, g, unknown or other
 <400> 1

```

aatccttttc ctggcacctc tgatatacct ttgaaattca tgttaaagaa tccctaggct      60
gcatcacat ctgggcattc tgttgagtac atgaataaat caactgggtg gttttacgaa      120
ggatgattat gcttcattgt gggattgtat ttttctcttc ctatcacagg gagaagtga      180
atgacaacct cactagatac agttgagacc tttggtacca catcctacta tgatgacgtg      240
ggcctgctct gtgaaaaagc tgataccaga gcactgatgg cccagtttgt gcccccgtg      300
tactccctgg tgttcactgt gggcctcttg ggcaatgtgg tgggtggtgat gatcctcata      360
aaatcacagga ggctccgaat tatgaccaac atctacctgc tcaacctggc catttcggac      420
ctgctctctc tcgtcacccct tccattctgg atccactatg tcaggggggc taactggggt      480
tttggccatg gcatgtgtaa gctcctctca ggggtttatc acacagggtt gtacagcgag      540
atctttttca taactctgct gacaatcgac aggtacctgg ccattgtcca tgctgtgttt      600
gcccttcgag cccgggactgt cacttttggg gtcataccca gcactgtcac ctggggcctg      660
gcagtgctag cagctctctc tgaatttacc ttctatgaga ctgaagagtt gtttgaagag      720
actctttgca gtgctcttta cccagaggat acagtatata gtggaggcca ttccacact      780
ctgagaatga ccactctctg tctcgtcttc cctctgctcg ttatggccat ctgctacaca      840
ggaatcatca aaacgctgct gaggtgcccc agtaaaaaaa agtacaaggc catccggctc      900
atttttgtca tcatggcggg gtttttcatt ttctggacac cctacaatgt ggctatcctt      960
ctctctctct atcaatccat cttatttgga aatgactgtg agcggagcaa gcacttggac      1020
ctgggtcacc tgggtacaga ggtgatcgcc tactccact gtgcatgaac cccggtgatc      1080
tacgctcttg ttggagagag gttccggaag tacctgcgcc acttctctca caggcaactg      1140
ctcatgcacc tgggcagata catcccatc ctctctagt agaagctgga aagaaccagc      1200
tctgtctctc catccacagc agagccggaa ctctctattg tgttttaggt agatgcagaa      1260
aattgcctaa agaggaagga ccaaggagat naagcaaaca cattaaacct tccacactca      1320
cctctcaaac agtctctcaa accttccagt gcaacactga agctcttaag acactgaaat      1380
atcacacagc cagttagcagt agatgcatgt accctaaggt cattaccaca gccacggggt      1440
ggcagcgcta ctcatcatca acctaaaaag cagagctttg ctctctctc taaaatgagt      1500
tacctatatt ttaatgcacc tgaatgttag atagttacta tatgccgcta caaaaaggta      1560
aaacttttta tttttatac attaatctta gccagctatt atataataaa aacattttca      1620
cacaatacaa taagttaact attttatctt ctaatgtgcc tagtctcttc cctgcttaat      1680
gaaaaagctt

```

<210> 2
 <211> 355
 <212> PRT
 <213> Homo sapiens
 <400> 2

```

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr
1      5      10      15
Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu
      20      25      30
Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly
      35      40      45
Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg
      50      55      60
Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp
      65      70      75      80
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly
      85      90      95
His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe
      100      105      110
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr
      115      120      125
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala

```

130 135 140
 Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu
 145 150 155 160
 Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu
 165 170 175
 Leu Phe Glu Glu Thr Leu Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val
 180 185 190
 Tyr Ser Trp Arg His Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu
 195 200 205
 Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys
 210 215 220
 Thr Leu Leu Arg Cys Pro Ser Lys Lys Lys Tyr Lys Ala Ile Arg Leu
 225 230 235 240
 Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn
 245 250 255
 Val Ala Ile Leu Leu Ser Ser Tyr Gln Ser Ile Leu Phe Gly Asn Asp
 260 265 270
 Cys Glu Arg Thr Lys His Leu Asp Leu Val Met Leu Val Thr Glu Val
 275 280 285
 Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val
 290 295 300
 Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Phe Phe His Arg His Leu
 305 310 315 320
 Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu
 325 330 335
 Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser
 340 345 350
 Ile Val Phe
 355

<210> 3

<211> 1193

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (92)..(1156)

<400> 3

ttgtgcttat ccgggcaaga acctatcgaa atacaataga agacccacgc gtcgggtttt 60
 tacttagaag agatttttcag ggagaagtga a atg aca acc tca cta gat aca 112
 Met Thr Thr Ser Leu Asp Thr
 1 5
 gtt gag acc ttt ggt acc aca tcc tac tat gat gac gtg ggc ctg ctc 160
 Val Glu Thr Phe Gly Thr Ser Tyr Tyr Asp Asp Val Gly Leu Leu
 10 15 20
 tgt gaa aaa gct gat acc aga gca ctg atg gcc cag ttt gtg ccc ccg 208
 Cys Glu Lys Ala Asp Thr Arg Ala Leu Met Ala Gln Phe Val Pro Pro
 25 30 35
 ctg tac tcc ctg gtg ttc act gtg ggc ctc ttg ggc aat gtg gtg gtg 256
 Leu Tyr Ser Leu Val Phe Thr Val Gly Leu Leu Gly Asn Val Val Val
 40 45 50 55
 gtg atg atc ctc ata aaa tac agg agg ctc cga att atg acc aac atc 304
 Val Met Ile Leu Ile Lys Tyr Arg Arg Leu Arg Ile Met Thr Asn Ile
 60 65 70
 tac ctg ctc aac ctg gcc att tcg gac ctg ctc ttc ctc gtc acc ctt 352
 Tyr Leu Leu Asn Leu Ala Ile Ser Asp Leu Leu Phe Leu Val Thr Leu
 75 80 85
 cca ttc tgg atc cac tat gtc agg ggg cat aac tgg gtt ttt ggc cat 400
 Pro Phe Trp Ile His Tyr Val Arg Gly His Asn Trp Val Phe Gly His
 90 95 100
 ggc atg tgt aag ctc ctc tca ggg ttt tat cac aca ggc ttg tac agc 448

Gly Met Cys Lys Leu Leu Ser Gly Phe Tyr His Thr Gly Leu Tyr Ser
 105 110 115
 gag atc ttt ttc ata atc ctg ctg aca atc gac agg tac ctg gcc att 496
 Glu Ile Phe Phe Ile Ile Leu Leu Thr Ile Asp Arg Tyr Leu Ala Ile
 120 125 130 135
 gtc cat gct gtg ttt gcc ctt cga gcc cgg act gtc act ttt ggt gtc 544
 Val His Ala Val Phe Ala Leu Arg Ala Arg Thr Val Thr Phe Gly Val
 140 145 150
 atc acc agc atc gtc acc tgg ggc ctg gca gtg cta gca gct ctt cct 592
 Ile Thr Ser Ile Val Thr Trp Gly Leu Ala Val Leu Ala Leu Pro
 155 160 165
 gaa ttt atc ttc tat gag act gaa gag ttg ttt gaa gag act ctt tgc 640
 Glu Phe Ile Phe Tyr Glu Thr Glu Glu Leu Phe Glu Glu Thr Leu Cys
 170 175 180
 agt gct ctt tac cca gag gat aca gta tat agc tgg agg cat ttc cac 688
 Ser Ala Leu Tyr Pro Glu Asp Thr Val Tyr Ser Trp Arg His Phe His
 185 190 195
 act ctg aga atg acc atc ttc tgt ctc gtt ctc cct ctg ctc gtt atg 736
 Thr Leu Arg Met Thr Ile Phe Cys Leu Val Leu Pro Leu Leu Val Met
 200 205 210 215
 gcc atc tgc tac aca gga atc atc aaa acg ctg ctg agg tgc ccc agt 784
 Ala Ile Cys Tyr Thr Gly Ile Ile Lys Thr Leu Leu Arg Cys Pro Ser
 220 225 230
 aaa aaa aag tac aag gcc atc cgg ctc att ttt gtc atc atg gcg gtg 832
 Lys Lys Lys Tyr Lys Ala Ile Arg Leu Ile Phe Val Ile Met Ala Val
 235 240 245
 ttt ttc att ttc tgg aca ccc tac aat gtg gct atc ctt ctc tct tcc 880
 Phe Phe Ile Phe Trp Thr Pro Tyr Asn Val Ala Ile Leu Leu Ser Ser
 250 255 260
 tat caa tcc atc tta ttt gga aat gac tgt gag cgg agc aag cat ctg 928
 Tyr Gln Ser Ile Leu Phe Gly Asn Asp Cys Glu Arg Ser Lys His Leu
 265 270 275
 gag ctg gtc atg ctg gtg aca gag gtg atc gcc tac tcc cac tgc tgc 976
 Asp Leu Val Met Leu Val Thr Glu Val Ile Ala Tyr Ser His Cys Cys
 280 285 290 295
 atg aac ccg gtg atc tac gcc ttt gtt gga gag agg ttc cgg aag tac 1024
 Met Asn Pro Val Ile Tyr Ala Phe Val Gly Glu Arg Phe Arg Lys Tyr
 300 305 310
 ctg cgc cac ttc ttc cac agg cac ttg ctc atg cac ctg gcc aga tac 1072
 Leu Arg His Phe Phe His Arg His Leu Leu Met His Leu Gly Arg Tyr
 315 320 325
 atc cca ttc ctt cct agt gag aag ctg gaa aga acc agc tct gtc tct 1120
 Ile Pro Phe Leu Pro Ser Glu Lys Leu Glu Arg Thr Ser Ser Val Ser
 330 335 340
 cca tcc aca gca gag ccg gaa ctc tct att gtg ttt taggtagatg 1166
 Pro Ser Thr Ala Glu Pro Glu Leu Ser Ile Val Phe
 345 350 355
 cagaaaattg cctaaagagg aaggacc 1193

<210> 4

<211> 355

<212> PRT

<213> Homo sapiens

<400> 4

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr
 1 5 10 15
 Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu
 20 25 30
 Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly
 35 40 45
 Leu Leu Gly Asn Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg

50	55	60
Leu Arg Ile Met Thr	Asn Ile Tyr Leu Leu	Asn Leu Ala Ile Ser Asp
65	70	75
Leu Leu Phe Leu Val Thr	Leu Pro Phe Trp Ile	His Tyr Val Arg Gly
	85	90
His Asn Trp Val Phe Gly	His Gly Met Cys Lys	Leu Leu Ser Gly Phe
	100	105
Tyr His Thr Gly Leu Tyr	Ser Glu Ile Phe Phe	Ile Ile Leu Leu Thr
	115	120
Ile Asp Arg Tyr Leu Ala	Ile Val His Ala Val	Phe Ala Leu Arg Ala
	130	135
Arg Thr Val Thr Phe Gly	Val Ile Thr Ser Ile	Val Thr Trp Gly Leu
	145	150
Ala Val Leu Ala Ala Leu	Pro Glu Phe Ile Phe	Tyr Glu Thr Glu Glu
	165	170
Leu Phe Glu Glu Thr Leu	Cys Ser Ala Leu Tyr	Pro Glu Asp Thr Val
	180	185
Tyr Ser Trp Arg His Phe	His Thr Leu Arg Met	Thr Ile Phe Cys Leu
	195	200
Val Leu Pro Leu Leu Val	Met Ala Ile Cys Tyr	Thr Gly Ile Ile Lys
	210	215
Thr Leu Leu Arg Cys Pro	Ser Lys Lys Lys Tyr	Lys Ala Ile Arg Leu
	225	230
Ile Phe Val Ile Met Ala	Val Phe Phe Ile Phe	Trp Thr Pro Tyr Asn
	245	250
Val Ala Ile Leu Leu Ser	Ser Tyr Gln Ser Ile	Leu Phe Gly Asn Asp
	260	265
Cys Glu Arg Ser Lys His	Leu Asp Leu Val Met	Leu Val Thr Glu Val
	275	280
Ile Ala Tyr Ser His Cys	Cys Met Asn Pro Val	Ile Tyr Ala Phe Val
	290	295
Gly Glu Arg Phe Arg Lys	Tyr Leu Arg His Phe	Phe His Arg His Leu
	305	310
Leu Met His Leu Gly Arg	Tyr Ile Pro Phe Leu	Pro Ser Glu Lys Leu
	325	330
Glu Arg Thr Ser Val Ser	Pro Ser Thr Ala Glu	Pro Glu Leu Ser
	340	345
Ile Val Phe		350
355		

<210> 5

<211> 1116

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic
consensus sequence

<400> 5

caggggagaag	tgaatgaca	acotcactag	atacagtiga	gacctttgggt	accacatcct	60
actatgatga	ctgtgggctgt	ctctgtgaaa	aagctgatac	cagagcactg	atggcccactg	120
ttgtgcccc	gctgtactcc	ctgggtgtca	ctgtgggctc	cttgggcaat	gtgggtgtgg	180
tgtatgctct	cataaaatc	aggaggctcc	gaattatgac	caacatctac	ctgctcaacc	240
tggccatttc	ggacctgtc	ttcctcgtca	cccttcatt	ctggatccac	tatgtcaggg	300
ggcataactg	ggtttttggc	catggcatgt	gtaagctcct	ctcagggttt	tatcacacag	360
gcttgtacag	cgagatcttt	ttcataatcc	tgctgacaat	cgacaggtag	ctggccattg	420
tcacgtctgt	gtttgcccct	cgagcccggg	ctgtcacctt	tggtgtcatc	accagcatcg	480
tcacctgggg	ctggcagtg	ctagcagctc	ttcctgaatt	tatcttctat	gagactgaag	540
agttgtttga	agagactmtt	tgccagtgtc	tttaccocaga	ggatacagta	tatagctgga	600
gssattttcca	cactctgaga	atgaccatct	tctgtctcgt	tctccctctg	ctcgttatgg	660
ccatctgcta	cacaggaatc	atcaaaaacg	tgctgaggtg	ccccagtaaa	aaaaagtaca	720
aggccatccg	gctcatcttt	gtcatcatgg	cgggtgtttt	cattttctgg	acaccttaca	780

```

atgtggctat ccttctctct tscywwymaw ycatcttatt tggaaatgac tgtgagcggm      840
mgarsmwyk  ggacctggct atgctgggtg cagaggtgat cgcctactcc cactgctgca      900
tgaacccggt gatctacgcc ttgttggag agaggttccg gaagtacctg cgccacttst      960
tccacaggca ctgtctcatg cacctgggca gatacatccc attccttctc agtgagaagc     1020
tggaaagaac cagctctgtc tctccatcca cagcagagcc ggaactctct attgtgtttt     1080
aggtagatgc agaaaattgc ctaaagagga aggacc      1116

```

<210> 6

<211> 355

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic consensus sequence

<220>

<221> MOD_RES

<222> (182)..(182)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (196)..(197)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (263)..(266)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (276)..(279)

<223> Any amino acid

<220>

<221> MOD_RES

<222> (315)..(315)

<223> Any amino acid

<400> 6

```

Met Thr Thr Ser Leu Asp Thr Val Glu Thr Phe Gly Thr Thr Ser Tyr
1      5      10      15
Tyr Asp Asp Val Gly Leu Leu Cys Glu Lys Ala Asp Thr Arg Ala Leu
      20      25      30
Met Ala Gln Phe Val Pro Pro Leu Tyr Ser Leu Val Phe Thr Val Gly
      35      40      45
Leu Leu Gly Asn Val Val Val Val Met Ile Leu Ile Lys Tyr Arg Arg
      50      55      60
Leu Arg Ile Met Thr Asn Ile Tyr Leu Leu Asn Leu Ala Ile Ser Asp
      65      70      75      80
Leu Leu Phe Leu Val Thr Leu Pro Phe Trp Ile His Tyr Val Arg Gly
      85      90      95
His Asn Trp Val Phe Gly His Gly Met Cys Lys Leu Leu Ser Gly Phe
      100      105      110
Tyr His Thr Gly Leu Tyr Ser Glu Ile Phe Phe Ile Ile Leu Leu Thr
      115      120      125
Ile Asp Arg Tyr Leu Ala Ile Val His Ala Val Phe Ala Leu Arg Ala
      130      135      140
Arg Thr Val Thr Phe Gly Val Ile Thr Ser Ile Val Thr Trp Gly Leu
      145      150      155      160
Ala Val Leu Ala Ala Leu Pro Glu Phe Ile Phe Tyr Glu Thr Glu Glu
      165      170      175
Leu Phe Glu Glu Thr Xaa Cys Ser Ala Leu Tyr Pro Glu Asp Thr Val
      180      185      190
Tyr Ser Trp Xaa Xaa Phe His Thr Leu Arg Met Thr Ile Phe Cys Leu
      195      200      205

```

```

Val Leu Pro Leu Leu Val Met Ala Ile Cys Tyr Thr Gly Ile Ile Lys
  210                215                220
Thr Leu Leu Arg Cys Pro Ser Lys Lys Tyr Lys Ala Ile Arg Leu
  225                230                235                240
Ile Phe Val Ile Met Ala Val Phe Phe Ile Phe Trp Thr Pro Tyr Asn
  245                250                255
Val Ala Ile Leu Leu Ser Xaa Xaa Xaa Xaa Ile Leu Phe Gly Asn Asp
  260                265                270
Cys Glu Arg Xaa Xaa Xaa Xaa Asp Leu Val Met Leu Val Thr Glu Val
  275                280                285
Ile Ala Tyr Ser His Cys Cys Met Asn Pro Val Ile Tyr Ala Phe Val
  290                295                300
Gly Glu Arg Phe Arg Lys Tyr Leu Arg His Xaa Phe His Arg His Leu
  305                310                315                320
Leu Met His Leu Gly Arg Tyr Ile Pro Phe Leu Pro Ser Glu Lys Leu
  325                330                335
Glu Arg Thr Ser Ser Val Ser Pro Ser Thr Ala Glu Pro Glu Leu Ser
  340                345                350
Ile Val Phe
  355

```

```

<210> 7
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
       primer
<220>
<221> modified_base
<222> (19)..(19)
<223> Inosine
<220>
<221> modified_base
<222> (24)..(24)
<223> Inosine
<400> 7
tacctgctsa acctggccnt ggcn

```

25

```

<210> 8
<211> 25
<212> DNA
<213> Artificial Sequence
<220>
<223> Description of Artificial Sequence: Synthetic
       primer
<220>
<221> modified_base
<222> (9)..(9)
<223> Inosine
<220>
<221> modified_base
<222> (14)..(14)
<223> Inosine
<400> 8
acctggccnt ggcnacctm ctctt

```

25

```

<210> 9
<211> 27
<212> DNA
<213> Artificial Sequence

```

<220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (18)..(18)
 <223> Inosine
 <400> 9
 gaccggtacc tggccatngt ccaygcc

27

<210> 10
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (10)..(10)
 <223> Inosine
 <400> 10
 ggcrctggacn atggccaggt arcggtc

27

<210> 11
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (1)..(1)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (6)..(6)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (16)..(16)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (18)..(18)
 <223> Inosine
 <400> 11
 naccanrttg taggggnrnc armarag

27

<210> 12
 <211> 28
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer

<220>
 <221> modified_base
 <222> (8)..(8)
 <223> Inosine

<220>
 <221> modified_base
 <222> (10)..(10)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (23)..(23)
 <223> Inosine
 <400> 12
 tgtagggnrn ccarmaragr agnargaa

28

<210> 13
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <220>
 <221> modified_base
 <222> (12)..(12)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (15)..(16)
 <223> Inosine
 <400> 13
 gaaggcgtag ansanngggt tgasgca

27

<210> 14
 <211> 25
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <220>
 <221> modified_base
 <222> (4)..(4)
 <223> Inosine
 <220>
 <221> modified_base
 <222> (7)..(8)
 <223> Inosine
 <400> 14
 agansanngg gttgasgtag cwgtg

25

<210> 15
 <211> 48
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide
 <220>
 <221> CDS
 <222> (16)..(48)
 <400> 15
 aagcttccag cagcc atg gac tac aag gac gac gat gac aaa gaa ttc
 Met Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe
 1 5 10

48

<210> 16
 <211> 11
 <212> PRT
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 peptide
 <400> 16
 Met Asp Tyr Lys Asp Asp Asp Asp Lys Glu Phe
 1 5 10

<210> 17
 <211> 27
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <400> 17
 ttaagaattc acaacctcac tagatac

27

<210> 18
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence: Synthetic
 primer
 <400> 18
 catagtggat ccagaatg

18

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (*i.e.*, GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.